Mpox: What You Need to Know
We have complied some of our news stories and interviews from the last week to offer information on the differences between clade I and clade 2 mpox, why WHO declaring the global emergency is significant, looking at mpox in the United States, and more.
Mpox and Concerns Around the Disease in the United States
Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.
The Significance of WHO Declaring Mpox a Global Emergency
Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.
The declaration was based on the outbreak's severity compared to past events and the differences between mpox Clade I and Clade II, which affect response strategies.
SIGA Technologies' Trial Results Benefits Mpox Treatment Despite Not Meeting Primary Endpoint
The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.
Sweden Reports Case of Mpox Clade I, First Case Outside Africa
The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.
Results reveal that the antiviral did not significantly improve lesion resolution in mpox patients compared to placebo, but it did report a lower mortality rate among participants than that seen in the broader DRC cases.
Africa CDC Director General: Mpox Outbreak a Public Health Emergency of Continental Security
This is the very first such declaration by the Africa CDC since its inception in 2017.
The WHO has also provided more information regarding common questions around the disease.
